A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP	Chromosome Aberrations, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Philadelphia Chromosome, Translocation, Genetic, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm	Active, not recruiting	Phase 3	2026-08-28		NCT04971226

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Novartis Pharmaceuticals	432

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Avera Cancer	Sioux Falls	United States	4
Chattanooga Onc And Hem Assoc PC	Chattanooga	United States	1
Florida Cancer Specialists	Fort Myers	United States	15
Florida Cancer Specialists Pan	Tallahassee	United States	2
Oregon Health Sciences University	Portland	United States	33
Rocky Mountain Cancer Centers	Denver	United States	26
Texas Oncology	Dallas	United States	7
Texas Oncology	Amarillo	United States	3
Texas Oncology-Baylor USO	Dallas	United States	1
Uni of Massachusetts Medical Center	Worcester	United States	1
University of Kentucky	Lexington	United States	98
Wake Forest University Baptist Medical Center	Winston-Salem	United States	11
Williamette Cancer Center	Eugene	United States	2